Navigation Links
Encision's Active Electrode Monitoring Technology Recommended at Minimally Invasive Gynecology Congress
Date:11/17/2010

BOULDER, Colo., Nov. 17, 2010 /PRNewswire/ -- Active electrode monitoring developed and manufactured by Boulder-based Encision Inc. (Pink Sheets: ECIA), is the only monopolar energy technology proposed as a solution to eliminate visceral burns during Single Port Laparoscopy according to a recent study presentation.  Encision is a medical device company owning patented surgical technology that is emerging as a standard of care in minimally invasive surgery.

The recommendations come as a result of a study reported by Dr. Basim Abu-Rafea at the 39th  American Association of Gynecological Laparoscopists Global Congress of Minimally Invasive Gynecology.  Dr. Abu-Rafea's paper, Single Port Laparoscopy and Monopolar Electrosurgery May Result in Visceral Burns, examined the effects of monopolar electrosurgery on various tissues/organs during simulated single port laparoscopic surgery in vitro and in vivo.

Dr. Abu-Rafea's conclusion was that "Monopolar electrosurgery during endoscopic surgery, compared with other energy sources, is associated with unique inherent risks and complications due to inadvertent direct coupling, capacitive coupling and insulation failure."  Dr. Abu-Rafea continued, "These dangers become particularly important with the emergence of single port laparoscopy which requires close proximity and crossing of multiple intra-abdominal instruments."  

Dr. Abu-Rafea also added, "During single port laparoscopy and use of monopolar energy, the proximity and crossing of instruments generates capacitive and/or direct coupled currents which may cause visceral burns.  Proposed solutions include the use of active electrode monitoring when performing single port laparoscopy to prevent capacitive coupling and direct coupling or consider using other forms of energy such as harmonic or bipolar."  

Jack Serino, Encision's president and CEO, responded in saying, "We are pleased that Encision's active electrode monitoring technology was again recognized as an important consideration to avoid inadvertent patient burns with the growing popularity of single port laparoscopy."

Encision Inc. designs, develops, manufactures and markets innovative surgical devices that allow surgeons to optimize technique and patient safety during a broad range of surgical procedures. The Company pioneered the development of patented AEM® Laparoscopic Instruments to improve electrosurgery and reduce the chance for patient injury in minimally invasive surgery.

In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Company notes that statements in this press release and elsewhere that look forward in time, which include everything other than historical information, involve risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. Factors that could cause the Company's actual results to differ materially include, among others, its ability to increase net sales through the Company's distribution channels, its ability to compete successfully against other manufacturers of surgical instruments, insufficient quantity of new account conversions, insufficient cash to fund operations, delay in developing new products and receiving FDA approval for such new products and other factors discussed in the Company's filings with the Securities and Exchange Commission. Readers are encouraged to review the risk factors and other disclosures appearing in our filings with the Securities and Exchange Commission. We do not undertake any obligation to update publicly any forward-looking statements, whether as a result of the receipt of new information, future events, or otherwise.

CONTACT:

Marcia McHaffie, Encision Inc., 303-444-2600, mmchaffie@encision.com




'/>"/>
SOURCE Encision Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ActiveSight and CHDI Leverage Fragment-Based Lead Discovery for Huntington Disease Therapies
2. New Minimally Invasive Breast Reconstructive Procedure for Breast Cancer Patients - Actively Recruiting Participants for Clinical Study
3. Semafores PI3 Kinase Inhibitor SF1126 is Active Against Tumor and Tumor Cells and Synergizes with Standard Chemotherapy Agents
4. Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus
5. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
6. New CoMotion(R) Trials Software by General Dynamics Enables Rapid, Interactive Sharing of Real-time Data for Clinical Trials
7. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
8. Human Genome Sciences Reports Positive Long-Term Data for LymphoStat-B in Patients With Active Systemic Lupus Erythematosus
9. Results Published in the Journal Cancer Demonstrate that Oral Talactoferrin Alfa is Active as Monotherapy in Previously Treated Patients with Metastatic Renal Cell Carcinoma
10. Going Beyond Spa Day: Giving Women the Opportunity to Do Something Proactive Which May Lead to Long Term Health Benefits
11. Radioactive Seed Therapy Shows Significant Reduction in Lung Cancer Recurrence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017 Research ... "Global Biosimilar Pipeline and Market Prospects: Addressing Production Complexities ... to their offering. ... "Global Biosimilar Pipeline and Market Prospects: Overcoming ... provides an in-depth assessment of the current trends in ...
(Date:4/20/2017)... April 20, 2017   ZappRx, Inc ., a digital ... prescribing process, today announced it closed $25 million in Series ... capital firm based in Seattle that ... Partners . The Series B round included participation from ... 2014, and GV (formerly Google Ventures). As part ...
(Date:4/20/2017)... Sweden , April 20, 2017 ... NEVPF) ("NeuroVive") today announced positive preclinical results ... preclinical compound for non-alcoholic steatohepatitis (NASH), in ... NV556 has previously shown ... NASH model. Today, NeuroVive,s scientists present novel ...
Breaking Medicine Technology:
(Date:4/26/2017)... St. Louis, Missouri (PRWEB) , ... April 26, ... ... optimal cost, quality and clinical outcomes, today released the podcast, “Make Plans ... Act in bringing value-based payment into the physician's office and how physicians and ...
(Date:4/26/2017)... N.J. (PRWEB) , ... April 26, 2017 , ... ... Inc. in Hackensack, N.J. has been honored by Enterprising Women magazine as ... that recognizes the world’s top women business owners. Winners have demonstrated that they ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... launched a unique website ( CRISPRCas.pioneer.com ) that demonstrates how this advanced plant ... produce more and better food, with fewer resources. It highlights the business’ principles, ...
(Date:4/25/2017)... ... April 25, 2017 , ... Splashtop Inc. , ... . This new addition to the Mirroring360 product family combines device screen mirroring ... Mirroring360 Pro enables educators, business professionals and individuals to stream or mirror app ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... attempts to compare student test score performance for the 2015-16 school year across ... state’s voucher programs. Though it highlights important patterns in student test score performance, ...
Breaking Medicine News(10 mins):